<DOC>
	<DOCNO>NCT02109016</DOCNO>
	<brief_summary>The purpose study determine whether lucitanib safe effective treatment patient advanced/metastatic lung cancer fibroblast growth factor ( FGF ) , vascular endothelial growth factor receptor ( VEGF ) , platelet derive growth factor ( PDGF ) relate genetic alteration .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety VEGFR-FGFR Inhibitor , Lucitanib , Given Patients With Advanced/Metastatic Lung Cancer FGF , VEGF , PDGF Related Genetic Alterations</brief_title>
	<detailed_description>Lucitanib oral inhibitor tyrosine kinase activity FGFR 1-3 , VEGFR 1-3 , PDGFR α/β . Lucitanib demonstrate potent anti-tumor anti-angiogenic activity vitro proliferation assay vivo use human tumor xenograft model , trend strong efficacy genomic aberrancy FGF PDGF . Abnormalities FGF , VEGF , PDGF-related gene observe across lung cancer histology . The first human trial lucitanib demonstrate daily lucitanib clinically active patient advance solid tumor . Specifically , patient FGFR1-amplification appear derive particular benefit lucitanib . Based result , study design explore safety anti-tumor activity daily lucitanib lung cancer patient FGF , VEGF , PDGF genetic alteration .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histologically cytologically confirm advanced/metastatic SCLC NSCLC Any follow tumor tissue base genetic alteration : FGFR1 , FGFR2 , FGFR3 , VEGFA , PDGFRα amplification ; Any FGFR1 , FGFR2 , FGFR3 gene fusion ; FGFR1 , FGFR2 , FGFR3 activate mutation Availability tumor tissue sample suitable central confirmation genetic alteration exploratory analyse Eastern Cooperative Oncology Group ( ECOG ) 0 1 Measurable disease per RECIST 1.1 Documented radiographic disease progression follow least one line therapy advanced/metastatic setting Tumors invade major vessel ; NSCLC tumor abut major vessel Uncontrolled hypertension , define SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg optimize antihypertensive therapy Uncontrolled hypothyroidism define serum thyroid stimulate hormone ( TSH ) high 5 mIU/mL receive appropriate thyroid hormone therapy Symptomatic and/or untreated central nervous system metastases Presence another active cancer Ongoing adverse event surgery prior anticancer therapy , include radiation , target , cytotoxic therapy Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>FGFR1 amplification</keyword>
	<keyword>FGF alteration</keyword>
	<keyword>VEGF alteration</keyword>
	<keyword>PDGF alteration</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>FGFR inhibitor</keyword>
	<keyword>PDGFR inhibitor</keyword>
	<keyword>VEGFR-FGFR inhibitor</keyword>
</DOC>